Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Expands Stock Repurchase Program

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics today said that its board of directors has authorized the repurchase of an additional $100 million of the firm's outstanding common stock.

The Salt Lake City-based molecular diagnostics firm already repurchased $100 million of its common stock under the initial repurchase program started this past May. It plans to repurchase the additional shares on the open market or through privately negotiated purchases and expects to complete the program by June 30, 2011.

"The expansion of our stock repurchase program reflects our confidence in the long-term potential for Myriad Genetics and our commitment to increasing shareholder value by returning capital to our shareholders," Myriad CFO James Evans said in a statement.

In early Tuesday trade on the Nasdaq, shares of Myriad were up 1 percent at $15.80.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.